Pulmatrix, Inc. annual report, FY2015

Filing identity and reporting period

The supplied filing is Ruthigen, Inc.’s Form 10-K for the fiscal year ended March 31, 2015, filed June 9, 2015. It is not a Pulmatrix, Inc. filing and does not report a calendar-year 2014 fourth quarter; the requested company and period therefore do not match the document.

Business context

Ruthigen was a clinical-stage biopharmaceutical company developing RUT58-60, a hypochlorous-acid-based candidate intended to prevent infection during abdominal surgery. It had no products approved for sale and no revenue. Its Phase 1/2 trial was evaluating safety, tolerability, and potential efficacy as an adjunct to systemic antibiotics. The company reported no serious adverse events to date.

Financial results and liquidity

Operating cash use increased with the larger net loss, partly offset by noncash stock compensation and changes in working capital. Investing cash use was $156,000, primarily for property and equipment; financing cash provided $328,000, including IPO over-allotment proceeds, net of repayment of advances from Oculus. Year-end liabilities were $635,000, all current; the balance sheet reported no debt. Accumulated deficit was $10.360 million. No gross margin was reported because there were no sales.

Changes, outlook, and material matters

• Compared with FY2014, R&D expense rose 58%, mainly due to RUT58-60 development and clinical-trial preparations. SG&A rose 161%, reflecting higher public-company legal, accounting, and insurance costs and $1.079 million of noncash stock compensation.
• Management said existing cash was expected to fund stand-alone operations through the quarter ending June 30, 2016, but would not fund later clinical development, regulatory approval, or commercialization. Management estimated approximately $50 million in total operating expense to bring RUT58-60 through its FDA-approval goal, based on its then-current plan.
• On March 13, 2015, Ruthigen agreed to merge with privately held Pulmatrix. The merger was pending at the filing date and subject to closing conditions, including stockholder approvals and minimum unrestricted cash of $9.0 million for a closing by July 31, 2015, or $8.85 million for a closing by August 13, 2015. Former Pulmatrix holders were expected to own approximately 83% of the combined company; the transaction would be accounted for as a reverse acquisition.
• The merger agreement allowed Ruthigen to scale down operations and required it to scale back RUT58-60 trial enrollment. The combined company was expected to focus on Pulmatrix’s pipeline; it could seek to sell or assign Ruthigen’s pre-merger assets. Estimated merger transaction costs were approximately $3.6 million, including $2.4 million cash and $1.2 million stock.
• Oculus, the former parent and technology licensor, sold 350,000 Ruthigen shares for $2.75 per share in March 2015 and had agreed to sell additional shares subject to the merger. A side letter provided for a potential sale process for Ruthigen’s pre-merger business, Oculus’s right of first refusal on qualifying sales, and a 10% payment to Oculus if sale proceeds exceeded $10 million.
• The Oculus shared-services agreement ended April 6, 2015. Ruthigen stated that it had arranged third-party manufacturing and analytical testing. Its license agreement with Oculus included up to $8 million in development milestones and sales royalties of 3% to 20%; no milestone liability had been accrued at year-end.
• The company reported no pending legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and internal control over financial reporting. The independent auditor gave an unqualified opinion on the financial statements but did not audit internal control effectiveness.

Key risks and investor verification

Ruthigen remained loss-making and dependent on external capital, clinical progress, regulatory approval, and third-party manufacturing. The merger could materially redirect the business and dilute existing holders; its completion, minimum-cash conditions, trial plans, and disposition of RUT58-60 were uncertain. Other material risks included clinical and regulatory failure, lack of commercial partners, limited trading liquidity, potential dilution from warrants and equity awards, and dependence on licensed intellectual property.

1. Verify the filing entity and period: this is Ruthigen’s FY2015 10-K, not Pulmatrix’s 2014 Q4 report.
2. Verify whether the merger closed, whether its cash conditions were met, and the final ownership and share counts.
3. Check subsequent disclosures for RUT58-60 trial enrollment, safety findings, and any sale or assignment of the candidate or related rights.
4. Assess actual cash burn and financing after March 31, 2015 against the stated June 30, 2016 runway and planned development costs.
5. Review the merger’s final transaction costs, executive compensation and equity arrangements, and potential dilution from warrants and equity plans.